Background and objective: Several pieces of data imply that metabolic syndrome (Met S) increases the risk of stroke. The modified Rankin scale (MRS), a clinician-reported evaluation of global impairment, is frequently used to assess the outcomes of patients with acute ischemic stroke. Patients with Met S and AIS were examined using modified Rankin Scale scores to determine their prognosis. Methods: The study involved fifty patients hospitalised at the D Y Patil Medical College Kolhapur between October 2020 and August 2022 with acute ischemic stroke symptoms. Initial symptomatic atherothrombotic ischemic stroke was detected using the diagnostic criteria of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). They were utilising the NCEP ATP III criteria for metabolic syndrome evaluation. Mortality at three months was the primary outcome. (a Rankin modified score of 4-6) At three months, secondary outcomes included recovery, disability, and death. Results: Fifty individuals were hospitalised for the trial. In the present study, 62 per cent (31 out of 50) of ischemic stroke patients were found to have metabolic syndrome. Compared to patients without metabolic syndrome, 67.74% of those diagnosed had an MRS score of more than 3. In contrast, only 31.58% of those without metabolic syndrome had an MRS value larger than 3. Compared to persons who did not have metabolic syndrome, those who did were more likely to die (19%) and be handicapped (71%) than those who did not have metabolic syndrome (47% and 16%). The incidence of discharge was significantly higher among individuals without metabolic syndrome (37%) compared to those with metabolic syndrome (10%). Conclusion: According to the results of our research, Met S was shown to be associated with a bad outcome in individuals diagnosed with acute ischemia. The development of efficient prophylactic interventions against metabolic syndrome and its separate components is required to bring the risk of future strokes down to a more manageable level.